Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nerandomilast→

Nerandomilast Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1423719-30-5
Molecular formula
C20H25ClN6O2S
Molecular weight
449 g/mol
Drug class
Preferential phosphodiesterase 4B (PDE4B) inhibitorantifibrotic and immunomodulatory small molecule
Mechanism of action
Inhibits PDE4, with at least nine-fold preferential inhibition of PDE4B over PDE4A, PDE4C and PDE4D in vitro. This increases intracellular cAMP and reduces expression of profibrotic growth factors and inflammatory cytokines implicated in pulmonary fibrosis.
Indications / reported uses
  • Treatment of idiopathic pulmonary fibrosis (IPF) in adults
  • Treatment of progressive pulmonary fibrosis (PPF) in adults under the US product indication; it is not an acute bronchodilator or treatment for acute exacerbations

Sources: NLM DailyMed — JASCAYD (nerandomilast), label updated 14 August 2026 · FDA — Jascayd approval for PPF · FDA — Jascayd approval for IPF · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nerandomilast Environmental Risk Assessment (ERA) (the Nerandomilast ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.